Online Book Reader

Home Category

Rewired_ The Post-Cyberpunk Anthology - James Patrick Kelly [52]

By Root 1011 0
to approve the software? When was it submitted to them?”

Masika was beginning to look like he wished he’d kept his mouth shut, but there was no going back now. He admitted warily, “It hasn’t been submitted to them. It can’t be — that’s the whole problem. We need a bootleg machine, a decommissioned model with the satellite link disabled, so we can run the Yeyuka software without their knowledge.”

“Why? Why can’t they find out about it?”

He hesitated. “I don’t know if I can tell you that.”

“Is it illegal? Stolen?” But if it was stolen, why hadn’t the rightful owners licensed the damned thing, so people could use it?

Masika replied icily, “Stolen back. The only part you could call ‘stolen’ was stolen back.” He looked away for a moment, actually struggling for control. Then he said, “Are you sure you want to know the whole story?”

“Yes.”

“Then I’ll have to make a phone call.”

Masika took me to what looked like a boarding house, student accommodation in one of the suburbs close to the campus. He walked briskly, giving me no time to ask questions, or even orient myself in the darkness. I had a feeling he would have liked to have blindfolded me, but it would hardly have made a difference; by the time we arrived I couldn’t have said where we were to the nearest kilometre.

A young woman, maybe nineteen or twenty, opened the door. Masika didn’t introduce us, but I assumed she was the person he’d phoned from the hospital, since she was clearly expecting us. She led us to a ground floor room; someone was playing music upstairs, but there was no one else in sight.

In the room, there was a desk with an old-style keyboard and computer monitor, and an extraordinary device standing on the floor beside it: a rack of electronics the size of a chest of drawers, full of exposed circuit boards, all cooled by a fan half a metre wide.

“What is that?”

The woman grinned. “We modestly call it the Makerere supercomputer. Five hundred and twelve processors, working in parallel. Total cost, fifty thousand shillings.”

That was about fifty dollars. “How—?”

“Recycling. Twenty or thirty years ago, the computer industry ran an elaborate scam: software companies wrote deliberately inefficient programs, to make people buy newer, faster computers all the time — then they made sure that the faster computers needed brand new software to work at all. People threw out perfectly good machines every three or four years, and though some ended up as landfill, millions were saved. There’s been a worldwide market in discarded processors for years, and the slowest now cost about as much as buttons. But all it takes to get some real power out of them is a little ingenuity.”

I stared at the wonderful contraption. “And you wrote the Yeyuka software on this?”

“Absolutely.” She smiled proudly. “First, the software characterises any damaged surface adhesion molecules it finds — there are always a few floating freely in the bloodstream, and their exact shape depends on the strain of Yeyuka, and the particular cells that have been infected. Then drugs are tailor-made to lock on to those damaged adhesion molecules, and kill the infected cells by rupturing their membranes.” As she spoke, she typed on the keyboard, summoning up animations to illustrate each stage of the process. “If we can get this onto a real machine…we’ll be able to cure three people a day.”

Cure. Not just cut them open to delay the inevitable.

“But where did all the raw data come from? The RNA sequencing, the X-ray diffraction studies…?”

The woman’s smile vanished. “An insider at HealthGuard found it in the company archives, and sent it to us over the net.”

“I don’t understand. When did HealthGuard do Yeyuka studies? Why haven’t they published them? Why haven’t they written software themselves?”

She glanced uncertainly at Masika. He said, “HealthGuard’s parent company collected blood from five thousand people in southern Uganda in 2013. Supposedly to follow up on the effectiveness of their HIV vaccine. What they actually wanted, though, was a large sample of metastasising cells so they

Return Main Page Previous Page Next Page

®Online Book Reader